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cepted January 17, 2014.he aim of this study was to test the hypothesis that late potentials and fractionated electrogram activity are due to
delayed depolarization within the anterior aspects of right ventricular (RV) epicardium in experimental models of
Brugada syndrome (BrS).Background Clinical reports have demonstrated late potentials on signal-averaged electrocardiography (ECG) recorded in
patients with BrS. Recent studies report the appearance of late potentials and fractionated activity on bipolar
electrograms recorded in the epicardium of the RV outﬂow tract in patients with BrS.Methods Action potential and bipolar electrograms were recorded at epicardial and endocardial sites of coronary-perfused
canine RV wedge preparations, together with a pseudo-ECG. The transient outward potassium current agonist
NS5806 (5 mM) and the Ca2þ-channel blocker verapamil (2 mM) were used to pharmacologically mimic the BrS
genetic defect.Results Fractionated electrical activity was observed in RV epicardium, but not in endocardium, as a consequence of
heterogeneities in the appearance of the second upstroke of the epicardial action potential, and discrete
high-frequency spikes developed as a result of concealed phase 2 re-entry. In no case did we observe primary
conduction delay as the cause of the BrS ECG phenotype or of late potential or fractionated electrogram activity.
Quinidine (10 mM) and the phosphodiesterase-3 inhibitors cilostazol (10 mM) and milrinone (2.5 mM) restored
electrical homogeneity, thus abolishing all late potentials and fractionated electrical activity.Conclusions These data point to an alternative pathophysiological basis for late potentials and fractionated electrical activity
recorded in the right ventricle in the setting of BrS. We demonstrate an association of such activity with abnormal
repolarization and not with abnormal depolarization or structural abnormalities. (J Am Coll Cardiol 2014;63:
2037–45) ª 2014 by the American College of Cardiology FoundationBrugada syndrome (BrS) is a disease that causes vulnerability
to ventricular tachycardia (VT) and sudden cardiac death in
young adults with structurally normal hearts. The electro-
cardiographic (ECG) pattern of BrS is characterized by
the appearance of prominent J waves, often appearing as
ST-segment elevation in the right pre-cordial leads (1–3),
which are often concealed, but can be unmasked by vagal
stimulation and potent sodium-channel blockers (3,4). BrSrch Laboratory, Utica, New York; and the
harmacotherapy, University of Szeged, Szeged,
by grant HL47678 from the National Heart,
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, 2013; revised manuscript received Decemberhas been linked to mutations causing decreased inward
currents such as peak sodium-channel current (INa) or
L-type calcium-channel current (ICa) or increased outward
currents, especially the transient outward potassium current
(Ito) (5,6). The net outward shift of current during phase 1
of the epicardial action potential (AP) leads to accentua-
tion of the spike-and-dome morphology, most prominent-
ly in the epicardium of the right ventricular outﬂow tract
(RVOT) (3). Loss of the dome (phase 2 of the AP) and
consequent development of dispersion of repolarization
within epicardium and between epicardium and endocar-
dium create the substrate for phase 2 re-entry and poly-
morphic VT (7).
Previous clinical reports have demonstrated the presence
of late potentials on the signal-averaged ECG (SAECG) in
patients with BrS (8). These investigators also recorded
Abbreviations
and Acronyms
AP = action potential
BrS = Brugada syndrome
ECG = electrocardiography
EG = electrogram
ICa = L-type calcium-channel
current
INa = sodium-channel current
Ito = transient outward
potassium current
PDE = phosphodiesterase
RV = right ventricular
RVOT = right ventricular
outﬂow tract
SAECG = signal-averaged
electrocardiography
VF = ventricular ﬁbrillation
VT = ventricular tachycardia
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2038delayed potentials using a uni-
polar electrogram (EG) lead in-
troduced into the conus branch
through the right coronary ar-
tery. This activity was hypothe-
sized to be due to a “myocardial
abnormality” in the epicardium,
but not the endocardium, of
the RVOT. Other investigators
documenting late potentials on
SAECG in patients with BrS
have attributed this activity to
structural abnormalities and de-
layed conduction within the RV
(9,10). Using bipolar EGs, Nade-
manee et al. (11) demonstrated
late potentials and fractionated
activity in RVOT epicardium in
patients with BrS and hypothe-
sized that these represent regions
of delayed conduction or depo-larization defects. A recent publication by Sacher et al. (12)
demonstrated such activity in patients with BrS challenged
with potent sodium-channel blockers, and the investigators
likewise hypothesized that these are due to depolarization
defects.
The present study provides a test of this hypothesis using
experimental models that closely recapitulate the ECG and
arrhythmic manifestations of BrS. The principal focuses of
the study were to elucidate the cellular mechanisms involved
and to test the hypothesis that late potentials and fraction-
ated EG activity recorded from the epicardial surface of
experimental models of BrS are associated with the devel-
opment of abnormal repolarization rather than abnormal
depolarization.Methods
Wedge preparations. All experiments were carried out in
compliance with the Guide for Care and Use of Laboratory
Animals published by the National Institutes of Health
(publication no. NIH 85-23, revised 1996) and approved
by the Institutional Animal Care and Use Committee.
Detailed methods for isolation and recording of trans-
membrane activity from coronary-perfused canine RV
wedge preparations have been reported previously (13,14).
Brieﬂy, adult mongrel dogs (20 to 35 kg) of either sex were
used. Transmural wedge preparations were dissected (1.9 
0.9  0.9 cm to 3.2  1.6  1.3 cm) from the RV free wall
in the dogs. The preparations were cannulated via the
marginal branch of the right coronary artery and perfused
with cardioplegic solution (Tyrode’s containing 12 mmol/l
KCl). Nonperfused tissue was carefully removed using a
razor blade. The preparations were then placed in a tissue
bath and perfused with oxygenated Tyrode’s solution (mM:
NaCl 129, KCl 4, NaH2PO4 0.9, NaHCO3 20, CaCl2 1.8,MgSO4 0.5, and glucose 5.5; pH: 7.4). The perfusate was
delivered using a roller pump (Cole-Parmer, Niles, Illinois)
at a constant ﬂow rate of 8 to 10 ml/min and warmed to
37  0.5C.
The preparations were equilibrated in the tissue bath until
electrically stable, usually 1 h, while stimulated at a basic cycle
length of 1,000 ms using bipolar silver electrodes insulated
except at the tips, applied to the endocardial surface. A
transmural ECG was recorded using two electrodes con-
sisting of AgCl half-cells placed in the tissue bath, 1.0 to 1.5 cm
from the epicardial and endocardial surfaces of the preparation,
along the same axis as the transmembrane recordings (the
epicardial electrode was connected to the positive input of the
ECG ampliﬁer).
Transmembrane APs were simultaneously recorded in two
epicardial sites (Epi 1 [distal] and Epi 2 [proximal]; distance
from Epi 1 to Epi 2: approximately 5 to 10 mm) and in one
endocardial site, with the use of ﬂoating microelectrodes
(DC resistance: 10 to 20 MU) ﬁlled with 2.7-mol/l KCl,
each connected to a high-input impedance ampliﬁer. Im-
palements were obtained from the epicardial and endocardial
surfaces of the preparation at positions approximating the
transmural axis of the ECG recording. Two unipolar EGs
were placed in the epicardium or endocardium. Virtual bi-
polar EGs were derived as the difference of two unipolar
EGs.
Spike 2 software (Cambridge Electronic Design Ltd.,
Cambridge, United Kingdom) was used to record and
analyze the ECG, EGs, and the AP. NS5806, verapamil,
quinidine, cilostazol, and milrinone were dissolved in
dimethyl sulfoxide (10-mM stock).
Results
Using coronary-perfused canine RV wedge preparations,
we induced the Brugada phenotype by the addition of
NS5806 (5 mM) (an Ito activator) and verapamil (2 mM)
(a Ca2þ-channel blocker) to the coronary perfusate.
NS5806 has previously been shown to increase Ito in iso-
lated canine cardiomyocytes, resulting in augmentation of
the notched appearance of the RV AP, most notably in the
epicardium (15,16). NS5806 (5 mM) and verapamil (2 mM)
accentuated the AP notch in RV epicardium, leading to the
development of a prominent J point and ST-segment
elevation, characteristic of the Brugada phenotype. Late
potentials and fractionated activity were often observed in
the bipolar EGs comparable to those recorded in the clinical
cases reported by Nademanee et al. (11) (Fig. 1). The
accentuation of the AP notch in the epicardium, but not
the endocardium, generates a transmural voltage gradient
involved in the accentuated J waves in the ECG. The
fractionated EG activity was observed to have resulted from
the heterogeneity in the appearance of phase 2 of the AP. In
no case did we observe major delays in phase 0 depolariza-
tion or any type of conduction problem of the primary de-
polarization wave.
Figure 1
Heterogeneities in the Appearance of the Epicardial Action Potential Second Upstroke Gives Rise to
Fractionated Epicardial EG Activity in the Setting of BrS
(Left) Right pre-cordial lead recordings, unipolar (Uni) and bipolar (Bi) electrograms (EGs) recorded from the right ventricular outﬂow tract in a patient with Brugada syndrome
(BrS). Reprinted, with permission, from Nademanee et al. (11). (Right) Electrocardiogram (ECG), action potentials from an endocardial (Endo) and two epicardial sites (Epi1 and
Epi2), and a bipolar epicardial EG, all simultaneously recorded from a coronary-perfused right ventricular wedge preparation treated with NS5806 (5 mM) and verapamil (2 mM) to
induce the Brugada phenotype. Basic cycle length: 1,000 ms. DIST ¼ distal; M ¼ midmyocardial M cell region. Reproduced with permission from Nadamanee et al. (11).
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2039With longer exposure to the provocative agents, we
observed loss of the AP dome at some epicardial sites but
not others. This further accentuated the transmural voltageFigure 2
Concealed Phase 2 Re-Entry as the Basis for Late Potentia
Experimental Model of BrS
The panels from top to bottom show a bipolar EG, action potentials recorded from an en
coronary-perfused right ventricular wedge preparation exposed to NS5806 (5 mM) and vera
a different preparation. Heterogeneous loss of the dome at the epicardium caused local re-
late potentials and fractionated bipolar epicardial EG activity. No major delays in conduction
propagation of the AP (action potential) dome. Each panel shows results from a differentgradient, thus contributing to the manifestation of J waves,
often appearing as ST-segment elevation. The dispersion of
repolarization generated as a result of abbreviation of thel and Fractionated Bipolar EG Activity in an
docardial and two epicardial sites, and an ECG, all simultaneously recorded from a
pamil (2 mM) to induce the Brugada phenotype. Each panel (A–D) shows results from
excitation via a concealed phase 2 re-entry mechanism, leading to the development of
of the primary beat were observed. Basic cycle length¼ 1,000 ms. Arrows show the
preparation. Abbreviations as in Figure 1.
Figure 3
Difference in Bipolar EG Activity Recorded From Epicardium and Endocardium and Phase 2 Re-Entry–Induced VT in an
Experimental Model of BrS
(A) Concealed phase 2 re-entry gives rise to late potentials and fractionated bipolar EG activity recorded from epicardium (left panel) but not endocardium (right panel) in
an experimental model of BrS. Heterogeneous loss of the dome at the epicardium caused local re-excitation via a concealed phase 2 re-entry mechanism. Basic cycle
length ¼ 1,000 ms. (B) Phase 2 re-entry–induced ventricular ﬁbrillation. The phase 2 re-entrant beat produced a closely coupled extrasystole that precipitated an episode
of polymorphic tachycardia. Arrows show the propagation of the action potential dome. All traces were simultaneously recorded from a coronary-perfused right ventricular wedge
preparation exposed to NS5806 (5 uM) and verapamil (2 uM) to induce the Brugada phenotype. Abbreviations as in Figure 1.
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2040epicardial AP at some sites but not others, or in the endo-
cardium, created a window vulnerable to the development
of re-entrant arrhythmias. Propagation of the dome from
regions at which it was maintained to regions at which it
was lost caused local re-excitation via a phase 2 re-entrant
mechanism, leading to the development of very closely
coupled re-excitation of epicardium. More often than not,
because of its early appearance, the phase 2 re-entrant beat
was unable to propagate out of the epicardial focus in which
it was generated, thus resulting in “concealed phase 2 re-
entry,” which was not manifested as an extrasystole in the
ECG. This local activity, however, accentuated the inverted
T-wave and caused late potentials and fractionated activity
on EGs recorded in epicardium but not endocardium, very
similar to those observed in the clinical cases reported
by Nademanee et al. (11) (Figs. 2 to 4). Concealed phase 2
re-entry associated with the appearance of late potential
activity was observed in seven of seven wedge preparations.
The mean  SEM coupling interval of concealed phase 2
re-entrant beat and the delay in the appearance of the
associated high-frequency late potentials in the bipolar EG
were 117.5  8.2 ms (range: 81 to 138 ms) and 121.1  8.9
ms, respectively (n ¼ 7).
When the phase 2 re-entrant beat was able to exit the
epicardial focus in which it was generated, it produced a
closely coupled extrasystole capable of initiating VT/ven-
tricular ﬁbrillation (VF), as illustrated in Figure 3B. When
the temperature of the coronary perfusate was reduced to30C, verapamil (3 mM) alone was able to induce concealed
phase 2 re-entry and delayed potentials (Fig. 5).
Figure 5 illustrates an example of 2:1 alternans of con-
cealed phase 2 re-entry, giving rise to marked T-wave
alternans and 2:1 alternation in the appearance of the
epicardial EG late potential. In the presence of NS5806
(5 mM) and verapamil (2 mM), the introduction of a stim-
ulated premature beat (S2) restored homogeneity of the
transmural APs and abolished the late potential and frac-
tionated epicardial EG activity (Fig. 6).
Quinidine and cilostazol have been shown to suppress
arrhythmogenesis associated with BrS. Quinidine and
cilostazol have been reported to eliminate SAECG late
potentials in patients with BrS (17,18). In another series
of experiments, we tested the hypothesis that the
ameliorative effects of these 2 agents are due to the
effect of these agents to reverse the repolarization defect,
thus suppressing concealed phase 2 re-entry and late
potential activity. We tested the effects of quinidine and
two phosphodiesterase (PDE)-3 inhibitors, cilostazol
and milrinone. As illustrated in Figures 7 and 8, quin-
idine (10 mM), cilostazol (10 mM), and milrinone
(2.5 mM) all promptly restored the AP dome throughout
epicardium, thus dramatically reducing epicardial and
transmural dispersion of repolarization, normalizing the
ECG, abolishing concealed phase 2 re-entry, and
eliminating all late potential and fractionated epicardial
EG activity.
Figure 4
Comparison of the Late Potential and Fractionated
Bipolar EG Activity in a Patient With BrS
(Left) Bipolar right ventricular epicardial and endocardial EGs recorded from the
right ventricular outﬂow tract in a patient with BrS patient from the study by
Nademanee et al. (11). Yellow arrow denotes the site of EG recording (by Nade-
manee et al. [11]). (Right) Bipolar EGs recorded from the epicardial surface of
coronary-perfused canine right ventricular wedge models of BrS. All recordings
were obtained from preparations displaying concealed phase 2 re-entry. In all
cases, late potentials and fractionated EG activity were the result of repolarization
defects created by an inward shift in the balance currents active during the early
phases of the epicardial action potential. In no case did we observe primary im-
pulse conduction delays. In both clinical and experimental models, no late po-
tentials or fractionated activity was observed in the endocardial EGs. Abbreviations
as in Figure 1.
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It is well-established that mutations leading to a decrease in
inward currents (INa or ICa) or to an increase in outward
currents (Ito and IK-ATP) are capable of causing BrS in
humans (5,19–22). We used NS5806 (Ito agonist) andverapamil (ICa antagonist) to pharmacologically model the
BrS genotypes involved in a loss of function of ICa (BrS
types 3, 4, and 9) (23) and a gain of function of Ito (BrS
types 5, 6, and 10) (5,6,24,25) so as to induce the Brugada
phenotype in coronary-perfused canine RV wedge prepara-
tions. The NS5806-induced increase in Ito caused an out-
ward shift in the balance of current in the early phase of the
epicardial AP, leading to a moderate increase in notch in
epicardium but little change in endocardium. The greater
accentuation of the AP notch in epicardium than in
endocardium gives rise to an increase in transmural voltage
gradient, causing an increase in the magnitude of the J wave
(Figs. 7 and 8). The addition of verapamil to the coronary
perfusate caused a further outward shift in the balance of
current, leading to further accentuation of these parame-
ters. Longer exposure caused all-or-none repolarization at
the end of the epicardial AP phase 1, leading to loss or
delay of the AP dome at some epicardial sites. In some
preparations, the increased repolarization forces caused
variable delay in the appearance of the second epicardial AP
upstroke, leading to the appearance of low-voltage frac-
tionated activity in the bipolar EG recording, as previously
demonstrated in clinical recordings reported by Nadema-
nee et al. (11) (Fig. 1).
Loss of the dome and marked abbreviation of AP
duration at some epicardial sites but not others caused a
prominent increase in epicardial and transmural disper-
sion of repolarization, thus creating the substrate for the
development of phase 2 re-entry and VT (Figs. 2 and 3).
Conduction of the AP dome, from sites at which it was
maintained to sites at which it was lost, caused local re-
excitation via a phase 2 re-entry mechanism. In the ma-
jority of cases, phase 2 re-entry was concealed because the
extra beat was unable to exit the focus in which it was
generated. However, the concealed phase 2 re-entrant beat
was able to produce high-frequency late potentials and
fractionated bipolar EGs in epicardium but not
in endocardium (Figs. 2 to 4), comparable to clinical ob-
servations reported by Nademanee et al. (11) and Sacher
et al. (12).
The hypothesis proposed by Nademanee et al. (11) and
Sacher et al. (12) that late potentials and fractionated activity
recorded in the RVOT of patients with BrS are due to
depolarization defects is not supported by our results, which
provide an alternative explanation for the appearance of such
activity, based on the development of primary repolarization
defects. Our observations suggest that without the beneﬁt
of AP recordings, it is difﬁcult to discern between repolar-
ization and depolarization defects. It is noteworthy that
recordings of monophasic APs in the epicardium and
endocardium of the RVOT in patients with BrS have
demonstrated AP activity very similar to that recorded from
the canine coronary wedge preparations, with no major
transmural conduction delay (26,27).
One way to distinguish between the two mechanisms in
the clinic might be to examine the effect of rate or atrial
Figure 5 Alternans of “Concealed” Phase 2 Re-Entry Gives Rise to Alternans of Late Potential and T Wave
Traces as in Figure 2, all simultaneously recorded from a coronary-perfused right ventricular wedge preparation exposed to verapamil (3 mM) and hypothermia (30C) to induce
the Brugada phenotype. Arrows indicate successful conduction of the Epi2 AP dome in alternate beats to generate concealed phase 2 re-entry. Abbreviations as in Figure 1.
Figure 6
Effects of Stimulated Premature Beat on Action
Potentials and Fractionated Bipolar EG in an
Experimental Model of BrS
Stimulated premature beat (S2) restored homogeneity of action potentials and
abolished fractionated bipolar EG in this experimental model of BrS. Traces as
in Figure 2, all simultaneously recorded from a coronary-perfused right ventricular
wedge preparation exposed to NS5806 (5 mM) and verapamil (2 mM) to induce the
Brugada phenotype. Basic cycle length ¼ 1,000 ms. S1-S2 ¼ 240 ms. Arrow shows
the propagation of the AP (action potential) dome. Abbreviations as in Figure 1.
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2042premature responses. When due to delayed conduction, the
notched appearance should become accentuated with ac-
celeration of rate or prematurity, because delayed conductionalmost always becomes more accentuated at faster rates or
with prematurity. When due to repolarization problems,
the amplitude of the J wave should diminish due to
insufﬁcient time for Ito to reactivate, as in the example
illustrated in Figure 6. A word of caution: In the presence
of drugs with use-dependent actions to inhibit sodium- or
calcium-channel current, an opposite response may be
observed after an increase in rate or even after a single
premature beat. Indeed, in the presence of verapamil
(Fig. 6), the use-dependent inhibition of ICa leads to
accentuation of the repolarization defects. The reduced
repolarization defect with a single premature beat is due to
the fact that the reduction of Ito was greater than the
reduction of ICa after a single premature beat.
Another way to discern between depolarization and
repolarization defects as a cause of the BrS phenotype is
by observing the response to quinidine. The INa inhibitory
effect of quinidine is expected to accentuate late potential
and fractionated EG activity if due to a depolarization
defect. If, on the other hand, the BrS phenotype is due to a
repolarization defect, quinidine via its action to inhibit Ito
would be expected to reduce or abolish late potential and
fractionated EG activity, which is what we observed in our
preparations (Fig. 7).
Quinidine and cilostazol have been reported to eliminate
SAECG late potentials in patients with Brugada syndrome
(17,18) and to exert antiarrhythmic effects in this setting
(7,28–32). Our results provide support for the hypothesis
that the ameliorative effects of these agents are due to an
effect of these two agents to reverse the repolarization de-
fect, thus suppressing concealed phase 2 re-entry and late
potential activity (Figs. 7 and 8A). In addition, we dem-
onstrate that milrinone, another PDE-3 inhibitor, is a
potent agent capable of exerting ameliorative actions in the
Figure 7
Effects of Quinidine on the Repolarization Defects Involved in Phase 2 Re-Entry and Associated Late Potentials and
Fractionated Epi EG Activity in an Experimental Model of BrS
The addition of quinidine (10 mM) to the coronary perfusate reversed the repolarization defects, restored action potential homogeneity, normalized the ECG, and abolished phase
2 re-entry and associated late potentials on the bipolar EG. Traces as in Figure 2, all simultaneously recorded from a coronary-perfused right ventricular wedge preparation
exposed to NS5806 (5 mM) and verapamil (2 mM) to induce the Brugada phenotype. Abbreviations as in Figure 1.
Figure 8
Effects of Cilostazol and Milrinone on the Repolarization Defects Involved in Phase 2 Re-Entry and Associated Late Potentials
and Fractionated Bipolar Epi EG Activity in an Experimental Model of BrS
The addition of cilostazol (10 mM) (A) or milrinone (2.5 mM) (B) to the coronary perfusate reversed the repolarization defects, thus restoring the epicardial action potential
dome throughout, normalizing the ECG and abolishing phase 2 re-entrant activity and associated late potential and fractionated bipolar Epi EG. Traces as in Figure 2, all
simultaneously recorded from a coronary-perfused right ventricular wedge preparation exposed to NS5806 (5 mM) and verapamil (2 mM) to induce the Brugada phenotype.
Abbreviations as in Figure 1.
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2044setting of BrS syndrome (Fig. 8B). The ameliorative action
of cilostazol and milrinone is likely attributable to the
effect of these PDE inhibitors to increase cyclic adenosine
monophosphate and thus boost ICa, leading to a reversal of
the repolarization defect and permitting the development
of the ECG manifestations of BrS. Quinidine, and cil-
ostazol at higher concentrations (33), exert a direct effect
to block Ito.
Quinidine is used for primary and secondary prevention
and as adjunct therapy for BrS. The ameliorative effect of
the PDE inhibitors (especially cilostazol) and quinidine to
suppress the BrS phenotype is consistent with clinical
ﬁndings (28,30,31,34–37).
Finally, if the late potentials recorded in the anterior
surface of the RVOT do not reﬂect delayed conduction,
then why does ablation of these sites produce an amelio-
rative response, as reported by Nademanee et al. (11)? Our
hypothesis is that eliminating the cells displaying a high
density of Ito, known to reside in the RVOT, prevents the
development of the repolarization defects involved in the
Brugada ECG, phase 2 re-entry, and VT/VF. A lower level
of Ito is the basis for why female carriers are protected from
developing the ECG and arrhythmic manifestations of
BrS (38) and is the basis for the actions of quinidine and
cilostazol. We are endeavoring to test this hypothesis by
ablating the regions of concealed phase 2 re-entry and late
potentials in coronary-perfused RV wedge models of BrS.
Our preliminary results provide strong support for the
hypothesis, showing that ablation of the sites of abnormal
repolarization normalizes the ECG and prevents the
development of phase 2 re-entry and VT/VF (B. Patocskai
and C. Antzelevitch, unpublished data, January 2014).
Study limitations. As with all data derived from experi-
mental models, extrapolation of the data from in vitro
models to clinical practice must be done with due caution.
Conclusions
The present study explored the alternate hypothesis that the
late potentials observed on SAECG and fractionated bipolar
epicardial EGs are not due abnormal conduction or struc-
tural abnormalities in the RV epicardium, but may be
associated with the development of abnormal repolarization
giving rise to concealed phase 2 re-entry in epicardium.
Our results might prove helpful in better understanding
the cellular mechanisms underlying late potential and frac-
tionated EG activity in a variety of pathophysiological
conditions.
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